Sun Pharma acquires Pola Pharma to boost dermatology segment

Sun Pharma recently made an announcement to acquire Japan-based Pola Pharma. The deal, which will help Sun Pharma to strengthen its presence in dermatology segment across the globe, was struck for $1 million.

The firm has entered into a definitive agreement to acquire Pola Pharma, which is engaged in research and development, manufacture, sale and distribution of branded and generic products in Japan, Sun Pharma said.

Pola Pharma’s portfolio mainly comprises dermatology products. It has two manufacturing facilities in Saitama, with capabilities to manufacture topical products and injectables.